dapagliflozin sold brand names farxiga us forxiga eu among others medication used treat type also used treat adults heart failure chronic kidney common side effects include hypoglycaemia low blood sugar urinary tract infections genital infections volume depletion reduced amount water diabetic ketoacidosis common side effect type diabetic serious rare side effects include fournier dapagliflozin sodiumglucose inhibitor works removing sugar body developed bristolmyers squibb partnership astrazeneca world health organizations list essential commonly prescribed medication united states million dapagliflozin available generic medication dapagliflozin used along diet exercise usually glucose lowering medications improve glycaemic control adults type diabetes reduce risk hospitalization heart failure among adults type diabetes known cardiovascular disease cardiovascular risk factors including high blood pressure high cholesterol smokers dapagliflozin addition shown reduce rate decline kidney function kidney failure nondiabetic type diabetic dapagliflozin also considered option people type diabetes mellitus heart failure reduced ejection fraction lvef given regardless current diabetes status addition standard medical therapy recent studies indicated use dapagliflozin medications inhibitor class empagliflozin reduce risk worsening hf death hospitalization inhibitors useful reduce risk hospitalization heart failure people atherosclerotic cardiovascular disease small number metaanalyses cohort studies shown dapagliflozin superior others addition dapagliflozin indicated treatment adults heart failure reduced ejection fraction reduce risk cardiovascular death hospitalization heart european union indicated adults november european medicines agency ema stated dapagliflozin longer used treat type us food drug administration fda ema expanded indications dapagliflozin include treatment nondiabetic patients chronic kidney disease clinical trials shown following effects treatment diamond trial showed treatment periods weeks improvement excess proteins urine proteinuria significant deterioration kidneys filtration rate reversible within weeks dapagliflozin discontinuation significant mean loss bodyweight dapackd trial showed median treatment period years patients already ace arb therapy events sustained decline kidneys filtration rate kidney failure death occurred statistically around months later treatment group placebo group first months treatment however kidneys filtration rate worse treatment group placebo group slightly less negative treatment group placebo group since dapagliflozin leads heavy glycosuria sometimes grams per day lead rapid weight loss tiredness glucose acts osmotic diuretic effect cause polyuria diabetes lead dehydration increased amount glucose urine also worsen infections already associated diabetes particularly urinary tract infections thrush candidiasis rarely use drug including dapagliflozin associated necrotizing fasciitis perineum also called fournier dapagliflozin also associated hypotensive reactions concerns exist may increase risk diabetic metaanalysis showed inhibitors dapagliflozin statistically correlated increase diabetic ketoacidosis occurrence type ii diabetic however trials showed dapagliflozin caused additional diabetic ketoacidosis events type diabetic patients received dapagliflozin cause dehydration serious urinary tract infections genital yeast elderly people people kidney problems low blood pressure people diuretics assessed volume status kidney people signs symptoms metabolic acidosis ketoacidosis acid buildup blood also dapagliflozin cause serious cases necrotizing fasciitis perineum fournier gangrene people diabetes low blood sugar combined lessen risk developing ketoacidosis serious condition body produces high levels blood acids called ketones surgery fda approved changes prescribing information inhibitor diabetes medicines recommend stopped temporarily scheduled surgery canagliflozin dapagliflozin empagliflozin stopped least three days ertugliflozin stopped least four days scheduled symptoms ketoacidosis include nausea vomiting abdominal pain tiredness trouble glucose lowering effect dapagliflozin starts diminish ckd patients reduced kidney function egfr may effective glycemic control however recent studies demonstrated renoprotective effect reducing kidney function decline dapagliflozin still used reduce kidney function decline regardless diabetes status therefore dapagliflozin used diabetic patients ckd prevent kidney function decline interventions may needed glycaemic first synthesis dapaglifloxin disclosed patent filed bristol myers squibb two main carboncontaining fragments combined reaction aryl lithium trimethylsilylprotected gluconolactone trimethylsilyl groups removed treatment methanesulfonic acid methanol gives intermediate unwanted methoxy group anomeric centre removed reaction triethylsilane presence boron trifluoride etherate route well others developed manufacture drug dapagliflozin inhibits subtype sodiumglucose transport proteins responsible least glucose reabsorption kidney blocking transporter mechanism causes blood glucose eliminated combination metformin dapagliflozin standard treatment dose mg daily lowered compared metformin monotherapy patients inadequately controlled type diabetes normal renal protective effects heart failure attributed primarily haemodynamic effects inhibitors potently reduce intravascular volume osmotic diuresis natriuresis consequently may lead reduction preload afterload thereby alleviating cardiac workload improving left ventricular less onethousandth versus nmoll drug interfere intestinal glucose dapagliflozin international nonproprietary name united states adopted name fixeddose combination product dapagliflozinmetformin extendedrelease called xigduo july fixeddose combination saxagliptin dapagliflozin approved medical use european union sold brand name combination drug approved medical use united states february also sold brand name may fixeddose combination dapagliflozin saxagliptin metformin hydrochloride extendedrelease tablets approved united states improve glycemic control adults type diabetes used combination diet exercise fda granted approval qternmet xr combination drug approved use european union november sold brand name committee medicinal products human use chmp ema issued positive opinion dapagliflozin found effective several studies participants type main measure effectiveness level glycated haemoglobin gives indication well blood glucose two studies involving participants type diabetes dapagliflozin used alone decreased levels placebo dummy treatment four studies involving participants adding dapagliflozin diabetes medicines decreased levels adding placebo study involving participants type diabetes dapagliflozin used combination metformin least effective sulphonylurea another type diabetes medicines used combinations reduced levels longterm study involving participants type diabetes looked effects dapagliflozin cardiovascular heart circulation study indicated dapagliflozins effects line diabetes medicines also work blocking two studies involving participants type diabetes whose blood sugar controlled well enough insulin alone adding dapagliflozin mg decreased levels hours adding dapagliflozin approved medical use european union november marketed number european dapagliflozin approved medical use united states january us fda expanded indications dapagliflozin include treatment adults heart failure reduced ejection fraction reduce risk cardiovascular death hospitalization heart first particular drug class sodiumglucose cotransporter inhibitors approved treat adults new york heart associations functional class iiiv heart failure reduced ejection results dapahf declaretimi clinical trials demonstrated efficacy dapagliflozin compared placebo improving survival adults heart failure reduced ejection fraction showed reduction number hospitalizations worsening heart failure cardiovascular death allcause safety effectiveness dapagliflozin evaluated randomized doubleblind placebocontrolled study average age participants years participants male determine drugs effectiveness investigators examined occurrence cardiovascular death hospitalization heart failure urgent heartfailure participants randomly assigned receive oncedaily dose either mg dapagliflozin placebo inactive months people received dapagliflozin fewer cardiovascular deaths hospitalizations heart failure urgent heartfailure visits receiving july fda granted astrazeneca fast track designation us development dapagliflozin reduce risk hospitalization heart failure cardiovascular death adults following heart august detailed results phase iii dapackd trial reportedly showed dapagliflozin top standard care reduced composite measure worsening renal function risk cardiovascular renal death compared placebo patients chronic kidney disease stages elevated urinary albumin excretion results consistent patients without type april fda expanded indications dapagliflozin include reducing risk kidney function decline kidney failure cardiovascular death hospitalization heart failure adults ckd risk disease efficacy dapagliflozin improve kidney outcomes reduce cardiovascular death people chronic kidney disease evaluated multicenter doubleblind study february eu approved dapagliflozin extended use cover heart failure patients across full spectrum left ventricular ejection fraction lvef including mildly reduced preserved ejection generic version dapagliflozin approved us fda february cant sold october generic version approved canada may january committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization generic version forxiga authorized eu since november dapagliflozin viatris approved medical used european union march systematic review concluded dapagliflozin reduced heart failure hospitalization cardiovascular death allcause mortality patients hfref ie congestive heart failure httpsenwikipediaorgwikidapagliflozin